<DOC>
	<DOCNO>NCT00076609</DOCNO>
	<brief_summary>Capecitabine chemotherapeutic approve use breast colorectal cancer . The advantage capecitabine ( 1 ) oral drug ; ( 2 ) less toxic many chemotherapeutics . In off-label hepatocellular carcinoma ( HCC ) clinical study , response rate capecitabine 13 % . The botanical drug PHY906 -- currently manufacture pursuant GMP standard regulation -- use China 1800 year treat gastrointestinal-related ailment . Recently , preclinical study demonstrate PHY906 potentiate anti-tumor effect capecitabine . This trial evaluate safety efficacy PHY906 enhance anti-tumor effect capecitabine .</brief_summary>
	<brief_title>Study Botanical PHY906 Plus Capecitabine Advanced Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Men woman 18 80 year age histologic cytologic diagnosis HCC meet follow criterion : ( ) afetoprotein level &gt; 600 ng/mL ; ( b ) presence cirrhosis chronic hepatitis B C ; ( c ) characteristic enhancement pattern liver tumor triphasic CT scan MRI . All patient previously expose prior anticancer treatment must clear evidence progressive disease recent treatment regimen ( see Exclusion Criteria ) . In phase I ( dose find ) phase II ( efficacy ) portion study , patient may either prior chemotherapy ( chemotherapy naive ) , prior capecitabine chemotherapy , refractory toor relapse fromno two prior systemically administer treatment regimen . ( Chemoembolization regard context systemically administer treatment regimen . ) All patient phase I phase II portion study must least one previously unirradiated , bidimensionally measurable lesion computerize tomography ( CT ) magnetic resonance imaging ( MRI ) scan &gt; 20 mm ( conventional CT scan ) equal 10 mm ( spiral CT scan ) . Triphasic spiral CT MRI scan preferred equipment available . All CT scan employ “ hepatoma protocol ” image capture technique . Patients central nervous system ( CNS ) involvement appropriate treatment free progressive neurological deficit 28 day prior enrollment . Patients cirrhosis must ChildPugh cirrhosis severity classification great B. Baseline performance status must Eastern Cooperative Oncology Group ( ECOG ) 0 , 1 , 2 . Life expectancy must reasonably estimate &gt; 12 week . Women patient know capable conception negative serum pregnancy test ( betahuman chorionic gonadotropin [ bhCG ] ) within 2 week start study ; patient agree use adequate nonestrogenic birth control method , consistent institute ’ standard form contraception conception possible study . Provide write informed consent prior screen . Patients estimate ( Cockroft Gault equation ) power 40 calculated baseline creatinine clearance 3050 mL/min start dose capecitabine reduce 750 mg/m2 BID X 14 day ; dose PHY906 remain unchanged . Patients baseline creatinine clearance le 30 mL/min enrol trial . Patients ChildPugh cirrhosis severity classification C. Baseline abnormalities hepatic test ( AST &gt; 5.0 X study center upper limit normal ( ULN ) ; ALT &gt; 5.0 X study center ULN ; albumin &lt; 2.8 g/dL ; international normalized ratio prothrombin time ( INR ) &gt; 1.5 X study center ULN ; total bilirubin &gt; 3.0 x study center ULN ) . Baseline hemoglobin &lt; 10.0 g/dL ; total WBC &lt; 2.0 X 10 power 9/L ; absolute neutrophil count ( ANC ) &lt; 1.0 X 10 power 9/L ; platelet count &lt; 50.0 X 10 power 9/L . Patients pregnant breastfeed . Any prior radiation therapy ( small portal use palliation isolate , symptomatic , osseous metastasis ) must complete 21 day entry study evaluable lesion must include radiation portal . Patients may either treatment naive previous anticancer treatment ; previously treat may expose capecitabine two prior systemically administer treatment regimens allow . It require treatment complete less 21 day prior patient treat study . Chemoembolization hepatic resection regard systemically administer treatment regimen . Any treatmentrelated toxicity must resolve within 21 day prior study entry . Patients previous concurrent malignancy except inactive nonmelanoma skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence within last 3 year prior study entry . Patients know , untreated brain metastasis ineligible trial . Patients treat ( irradiate ) brain metastasis eligible treatment complete 28 day prior study entry clinical neurologic function stable . No patient , however , may enroll trial take phenytoin ( Dilantin ) . Patients carcinomatous meningitis , treat untreated , exclude study . Patients uncontrolled metabolic disorder nonmalignant organ systemic disease secondary effect cancer induce high medical risk . Patients receive warfarin ( Coumadin ) , coumarintype anticoagulant dose , even “ minidose , ” exclude study possible interference metabolism capecitabine . Known allergy hypersensitivity PHY906 component use PHY906 formulation , capecitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>advanced</keyword>
	<keyword>unresectable</keyword>
	<keyword>liver cancer</keyword>
	<keyword>systemic chemotherapy</keyword>
	<keyword>botanical</keyword>
	<keyword>herbal</keyword>
	<keyword>alternative complementary medicine</keyword>
	<keyword>capecitabine</keyword>
	<keyword>PHY906</keyword>
	<keyword>oral</keyword>
	<keyword>HCC</keyword>
	<keyword>traditional chinese medicine</keyword>
	<keyword>tcm</keyword>
	<keyword>QOL</keyword>
	<keyword>quality life</keyword>
</DOC>